1) Baselga, J., Herbst, R., LoRusso, P., et al. : Continuous administration of ZD1839(lressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerability. Proc. Am. Soc. Clin. Oncol., 19: 177a, 2000.
2) Bergsland, E., Hurwitz, H., Fehrenbacher, L., et al. : A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin(FU/LV) to FU/LV alone in patients with metastalic colorectal cancer. Proc. Am. Soc. Clin. Oncol., 19: 242a, 2000.
3) DeVore R. F., Fehrenbacher, L., Herbst, R. S., et al. : A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel(CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol., 19: 485a, 2000.
4) Ferry, D., Hammond, L., Ranson, M., et al. : Intermittent oral Zd1839(lressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor(Egfr-Tki), shows evidence of good tolerability and activity: final results from a phase I study. Proc. Am. Soc. Clin. Oncol., 19: 3a, 2000.
5) Fielding, J., Scholefield, J., Stuart, R., et al. : A randomized double-blind placebo-controlled study of marimastat in patients with inoperable gastric adenocarcinoma. Proc. Am. Soc. Clin. Oncol., 19: 240a, 2000.
